News

Exciting Developments in (Z)-Endoxifen Research at SABCS 2025

Exciting Developments in (Z)-Endoxifen Research at SABCS 2025

Atossa Therapeutics' Bold Moves in Breast Cancer Treatment

Atossa Therapeutics, Inc. (NASDAQ: ATOS) is making waves in the oncology sector, focusing on innovative therapies for breast cancer. The company has recently announced that four abstracts on (Z)-endoxifen have been accepted for presentation at the renowned San Antonio Breast Cancer Symposium (SABCS), scheduled for December 2025.

Significance of (Z)-Endoxifen in Cancer Treatment

(Z)-Endoxifen is gaining recognition for its potential in transforming breast cancer treatment paradigms. Research indicates that this compound could play a vital role in not just treatment, but also in the prevention of breast cancer. As Dr. Steven Quay, President and CEO of Atossa, points out, the company is dedicated to increasing the body of clinical evidence surrounding this promising compound.

Presentation Highlights and Topics

Details of the Presentations

Attendees at SABCS 2025 can look forward to compelling poster presentations that outline the findings from studies assessing (Z)-endoxifen's efficacy. The presentations will showcase research that includes:

  • Initial results from RECAST DCIS: This multicenter platform trial evaluates active surveillance along with novel endocrine therapy agents for managing Ductal Carcinoma In Situ (DCIS).
  • Low dose (Z)-endoxifen: Findings from the I-SPY2 Endocrine Optimization Pilot will also be revealed.
  • ER? Antagonist Function: Exploring how (Z)-endoxifen maintains activity against specific mutants through various mechanisms.
  • Neoadjuvant Treatment Approaches: A randomized Phase 2 trial comparing (Z)-endoxifen in combination with Goserelin versus traditional therapies for premenopausal women with ER+/HER2- breast cancer.

Anticipation for SABCS 2025

The anticipation for SABCS 2025 is palpable within the oncology community. With a commitment to rigorous clinical evidence, Atossa Therapeutics is set to shine a spotlight on important findings that could influence future treatment strategies. By presenting these innovative studies, the company hopes to engage with healthcare professionals and stakeholders dedicated to advancing breast cancer care.

About Atossa Therapeutics

Atossa Therapeutics, Inc. (NASDAQ: ATOS) is a forward-thinking clinical-stage biopharmaceutical firm focused on addressing significant unmet needs in the breast cancer landscape. Through strategic resource allocation and an emphasis on impactful data, Atossa aims to facilitate future regulatory submissions and ultimately bring its therapies to market.

Frequently Asked Questions

What is (Z)-endoxifen?

(Z)-Endoxifen is a metabolic derivative of tamoxifen that shows promise in breast cancer treatment and prevention.

Where will the SABCS 2025 take place?

The San Antonio Breast Cancer Symposium is scheduled to happen in San Antonio, Texas.

Who is presenting the abstracts at SABCS?

Dr. Steven Quay, the President and CEO of Atossa Therapeutics, will represent the company during the presentations at SABCS.

What are the key topics of discussion regarding (Z)-endoxifen?

Key topics include its role in treating DCIS, its effectiveness as a low-dose therapy, and its function against ESR1 mutants.

How can I find more information about Atossa Therapeutics?

More details about Atossa Therapeutics can be found on their official website and in their filings with the U.S. Securities and Exchange Commission.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Skyven's Heat Pump Sets New Steam Efficiency Benchmark

Updated Category News Views 3

The Efficiency Game-Changer in Industrial Steam Swinging in like a seasoned market shake-up is Skyven Technologies, raising eyebrows—and interest—by nailing a coefficient of performance (COP) of 8.0 for their Arcturus heat pump. You don't have to be a market wizard to know that's a big leap from the initial COP of 6.5. It's more than just numbers on a page; this...

Continue Reading
Ivonescimab Shows Strong Survival in Key Lung Cancer Trial

Updated Category News Views 0

New Frontiers in Lung Cancer Treatment Well, here's a story that rattles the cage in the oncology world. The name of the game is ivonescimab, Akeso’s latest move as they toss their hat into the already crowded yet pivotal lung cancer treatment ring. This isn't just some side hustle—they've got Phase III data pointin' straight north, figuratively casting a shadow over...

Continue Reading
Geek+ Spurs Growth with 35.5% Order Surge and New Model

Updated Category News Views 2

Unexpected Surge in Orders Drives Geek+ It looks like Geek+ isn't just playing around in the robotics sandbox anymore. They're delivering some serious results, reporting a 35.5% increase in new signed orders reaching a whopping RMB2.385 billion for the first half of 2026. That's not chump change, and it injects a healthy dose of optimism into their future performance...

Continue Reading
Art Ave Spurs Rebirth in Downtown DC: A Template for Revival

Updated Category News Views 0

Turning Streets into Art Galleries No one would have believed a stretch of DC's bureaucratic offices was about to morph into a vibrant destination worthy of major art aficionados. But here we are, tipping our hats to the Golden Triangle Business Improvement District (BID), who just snagged the IDA Downtown Achievement Award of Excellence for their Art Ave project. Not...

Continue Reading
PMI Foods Fuels Hunger Action Month with New Partnership

Updated Category News Views 2

Helping Families Put Food on the Table Out there in Utah's schoolyards, Parker Migliorini International (PMI Foods) is taking a tangible step against hunger, whipping out a $15,000 check to back the Utah Food Bank’s Mobile School Pantry initiative. This partnership kicks off in September, aligning with Hunger Action Month, a period dedicated to spotlighting food...

Continue Reading
Tradr's Bold Venture: Anthropic ETFs Ahead of IPO

Updated Category News Views 2

Why Tradr Is Diving Into Anthropic's Hype There's a whiff of anticipation in the air as Anthropic gears up for its much-anticipated IPO, and Tradr isn't sitting on its hands here. They've just filed for two ETFs—one long, one short—ahead of the big day. We're talking about ANTT and ANTZ, betting on leveraged and inverse plays on whatever whirlwind Anthropic's stock...

Continue Reading
California's Annual Recovery Happens Event Unites Community

Updated Category News Views 2

A Public Campaign for Recovery Awareness Anyone with a pulse on what's going on in the addiction recovery landscape knows the significance of events like Recovery Happens. It's not just another day in Sacramento; it's a rallying cry for change—a public affirmation that recovery is tangible and thriving. This isn't about showy gala dinners or fancy corporate events; it's...

Continue Reading
Wahl's Bold Move: The Baldscaper™ Revolution

Updated Category News Views 2

A Legacy of Grooming Innovation When Wahl, a brand that's been in the grooming game for over a century, decides to go all in on a new product, you better believe it's worth a look. Wahl's new Baldscaper™ isn't just another gadget in the grooming aisle—it's a statement. Going bald can be a bold choice, and with their latest unveil, Wahl seems to be rewarding every...

Continue Reading
Common Threads Takes Nutrition Education Digital in 2026

Updated Category News Views 4

Digitizing 23 Years of Nutrition Know-How Common Threads has been in the trenches for over two decades, teaching kids and families how to eat right and cook healthier meals. Now, the nonprofit's dragging its vast experience into the digital realm, rolling out a beefed-up version of its TEACH platform this September 15th. Through new certificate courses in Nutrition...

Continue Reading
York Space Systems Faces Class Action After IPO Issues

Updated Category News Views 1

What's Up with York Space Systems? Alright, let's dive straight into this unfolding drama. York Space Systems—fresh off their IPO in January 2026—is now neck-deep in a class action lawsuit courtesy of Robbins LLP. It's a heavy hitter for folks who put money into their stock under the assumption that it was as solid as a rock. Instead, there seems to be a soft...

Continue Reading

Top 5 Most Recently Viewed Articles

Tech Sector Gains Momentum as Market Reacts to Rate Cuts

Updated Category News Views 63

Market Overview: Modest Gains and Trader Optimism As the week kicks off, U.S. index futures are showing slight upticks, signaling that traders remain hopeful despite waning enthusiasm from the recent rate cuts. There's a growing expectation that the technology sector will support the market, especially with recent developments involving Intel Corp (NASDAQ: INTC)....

Continue Reading
BDA Strengthens Portfolio with Acquisition of Harper + Scott

Updated Category News Views 944

BDA Strengthens Portfolio with Acquisition of Harper + Scott Deal Grows BDA's Roster of Enterprise Customers, Unites Top Branded Merchandise Agencies Bensussen Deutsch & Associates, LLC (BDA), the nation's leading Merchandise Agency™ for iconic brands including Major League Baseball, Johnson & Johnson, and The Home Depot, has acquired Harper + Scott, a creative branded...

Continue Reading
Mexco Energy Corporation Achieves Growth Amid Oil Price Challenges

Updated Category News Views 170

Mexco Energy Corporation Reports Impressive Financial Performance Mexco Energy Corporation (NYSE American: MXC), based in Midland, Texas, has reported notable financial results for the recently concluded six-month period. The company has achieved a net income of $565,457, translating to $0.27 per diluted share for the interim period ending September 30. Operating Revenues...

Continue Reading
Exciting Developments in (Z)-Endoxifen Research at SABCS 2025

Updated Category News Views 167

Atossa Therapeutics' Bold Moves in Breast Cancer Treatment Atossa Therapeutics, Inc. (NASDAQ: ATOS) is making waves in the oncology sector, focusing on innovative therapies for breast cancer. The company has recently announced that four abstracts on (Z)-endoxifen have been accepted for presentation at the renowned San Antonio Breast Cancer Symposium (SABCS), scheduled for...

Continue Reading
JPMorgan Global Growth & Income Adds New Ordinary Shares

Updated Category News Views 202

JPMorgan Global Growth & Income Expands Share Capital Recently, JPMorgan Global Growth & Income Plc took an important step by issuing 100,000 new Ordinary Shares priced at 581.70 pence each. This decision to issue additional shares aligns with the company’s ongoing strategy to enhance its operational capacity and foster growth. Impact on Share Capital This issuance has...

Continue Reading